Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
As of close of business last night, Syndax Pharmaceuticals Inc’s stock clocked out at $14.15, up 3.28% from its previous closing price of $13.70. In other words, the price has increased by $3.28 from its previous closing price. On the day, 3.03 million shares were traded. SNDX stock price reached its highest trading level at $14.24 during the session, while it also had its lowest trading level at $13.185.
Ratios:
To gain a deeper understanding of SNDX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.82 and its Current Ratio is at 5.82. In the meantime, Its Debt-to-Equity ratio is 1.20 whereas as Long-Term Debt/Eq ratio is at 1.16.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, UBS on October 24, 2024, initiated with a Buy rating and assigned the stock a target price of $37.
On June 28, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $37.
Scotiabank Downgraded its Sector Outperform to Sector Perform on January 31, 2024, whereas the target price for the stock was revised from $36 to $23.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 04 ’25 when Metzger Michael A sold 7,814 shares for $15.05 per share. The transaction valued at 117,564 led to the insider holds 300,121 shares of the business.
MICHAEL METZGER bought 13,888 shares of SNDX for $214,986 on Mar 04 ’25. On Feb 10 ’25, another insider, Goldan Keith A., who serves as the Chief Financial Officer of the company, sold 3,777 shares for $15.50 each. As a result, the insider received 58,559 and left with 90,746 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SNDX now has a Market Capitalization of 1217522560 and an Enterprise Value of 980071168. For the stock, the TTM Price-to-Sale (P/S) ratio is 51.42 while its Price-to-Book (P/B) ratio in mrq is 4.21. Its current Enterprise Value per Revenue stands at 41.388 whereas that against EBITDA is -2.885.
Stock Price History:
The Beta on a monthly basis for SNDX is 0.83, which has changed by -0.35269898 over the last 52 weeks, in comparison to a change of 0.09969199 over the same period for the S&P500. Over the past 52 weeks, SNDX has reached a high of $25.07, while it has fallen to a 52-week low of $9.66. The 50-Day Moving Average of the stock is 6.95%, while the 200-Day Moving Average is calculated to be -14.80%.
Shares Statistics:
It appears that SNDX traded 2.06M shares on average per day over the past three months and 1633830 shares per day over the past ten days. A total of 85.69M shares are outstanding, with a floating share count of 84.18M. Insiders hold about 2.17% of the company’s shares, while institutions hold 111.88% stake in the company. Shares short for SNDX as of 1744675200 were 21168861 with a Short Ratio of 10.29, compared to 1741910400 on 18823847. Therefore, it implies a Short% of Shares Outstanding of 21168861 and a Short% of Float of 27.79.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
